Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 9, 2000, Pages 3409-3416

  Maheshwari, Hiralal G ^a   Prezant, Toni R ^a   Herman Bonert, Vivien ^a   Shahinian, Hrayr ^a   Kovacs, Kalman ^b   Melmed, Shlomo ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; FOLLITROPIN; GLUCOSE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; LUTEINIZING HORMONE; SOMATOMEDIN; SOMATOSTATIN; THYROTROPIN;

ADENOMA; ADOLESCENT; ARTICLE; CASE REPORT; ELECTRON MICROSCOPY; EPIPHYSIS DISEASE; FEMALE; GIGANTISM; GROWTH ACCELERATION; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0033693821     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.9.3409     Document Type: Article

References (39)

1. Pituitary gigantism
2. Gigantism due to pituitary mammosomatotroph hyperplasia
3. Use of cabergoline in the treatment of hyperprolactinemic and acromegalic patients
4. Cabergoline in the treatment of acromegaly: A study in 64 patients
5. Octreotide as primary treatment of acromegaly
6. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas
7. Acidophil stem cell adenoma of the human pituitary: Clinicopathologic analysis of 15 cases
8. Pituitary gigantism caused by growth hormone excess from infancy
9. Pathological and experimental investigation in a case of gigantism
10. Mammosomatotroph adenoma causing gigantism in an 8-year old boy: A possible pathogenetic mechanism
11. Gs α mutation at codon 201 in pituitary adenoma causing gigantism in a 6-year-old boy with McCune-Albright syndrome
12. McCune-Albright syndrome associated with a functioning pituitary chromophobe adenoma
13. Growth hormone (GH) secretory dynamics in a case of acromegalic gigantism associated with hyperprolactinemia: Nonpulsatile secretion of GH may induce elevated insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 levels
14. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: An analysis using the MIB-1 antibody
15. Adolescent acromegaly: Studies of growth-hormone and insulin metabolism
16. Pituitary gigantism in a 31 months old girl: Endocrine studies and successful response to hypophysectomy
17. The acromegaly-gigantism syndrome. Report of four cases treated surgically
18. Treatment of metastasising GRF-producing tumor with a long-acting somatostatin analogue
19. Management of pituitary gigantism. The role of bromocriptine and radiotherapy
20. Pituitary tumor causing gigantism. Morphology and in vitro hormone secretion
21. Acromegaly in an infant
22. Pituitary gigantism
23. Congenital gigantism due to growth hormone-releasing hormone excess and pituitary hyperplasia with adenomatous transformation
24. Suppression of GH secretion in pituitary gigantism by continuous subcutaneous octreotide infusions in a pubertal boy
25. Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone-secreting carcinoid
26. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly
27. Long-term treatment of acromegaly with the somatostatin analogue SR-lantreotide
28. Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor
29. GTPase inhibiting mutations activate the α chain of G(s) and stimulate adenylyl cyclase in human pituitary tumors
30. Two G protein oncogenes in human endocrine tumors
31. Identification of G protein α subunit mutations in human growth hormone (GH)- and GH/prolactin-secreting pituitary tumors by single-strand conformation polymorphism (SSCP) analysis
32. Identification of alternatively spliced messenger ribonucleic acid encoding truncated growth hormone-releasing hormone receptor in human pituitary adenomas
33. Allelic loss on chromosome 11 in hereditary and sporadic tumors related to familial multiple endocrine neoplasia type 1
34. Association of somatotrophinomas with loss of alleles on chromosome 11 and with gsp mutations
35. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states
36. Molecular characterization of the men1 tumor suppressor gene in sporadic pituitary tumors
37. Treatment of acromegaly with dopamine agonists
38. Somatostatin receptor (SSTR) subtypes-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors
39. Somatostatin receptors present knowledge and future directions